The speakers and agenda were as follows:
Stefano Del Prato, MD - Università di Pisa, Pisa, Italy
The High Risk Diabetes patient with cardiovascular disease:
What else can we target to reduce cardiovascular risk?
Kausik Ray, MD - Imperial College London, United Kingdom
Understanding BET inhibition as a novel pathway for cardiovascular risk modulation
Jorge Plutzky, MD - Brigham and Women's Hospital, Harvard Medical School, Boston, USA
BET inhibition in cardiovascular disease: A new dawn?
John Kastelein, MD - Academic Medical Centre, Amsterdam, The Netherlands
Discussion & summary
Stefano Del Prato, MD - Kausik Ray, MD
Presentations will be made available at: www.pace-cme.org.
Donald J. McCaffery, President and CEO commented, "The presentations at the ESC Congress symposium highlighted apabetalone and the opportunity and need for a novel approach to the treatment of high risk cardiovascular disease and diabetes. Moreover, data presented demonstrated the important role for epigenetics in the underlying pathology of these diseases". McCaffrey added that "based on its mechanism, we believe that apabetalone has the potential to address the significant unmet medical need in this patient population. Importantly, we remain encouraged by the recent data safety monitoring board review and recommendation to proceed with the BETonMACE phase 3 trial, as planned. The trial has already attained one quarter enrollment of the planned 2,400 patients and remains on track with internal projections."
Resverlogix also presented a poster at the congress entitled: "Modulation of the complement cascade in cardiovascular disease patients by a bromodomain and extraterminal (BET) protein inhibitor". The poster will be made available on the Resverlogix website at: http://www.resverlogix.com/media/presentations-publications.html#.V8Lq-pgrKhc.
The poster contained data demonstrating that apabetalone treatment reduced basal and cytokine-induced expression of complement factors in hepatocytes. Furthermore, in samples from CVD patients, the complement pathway was identified to be the top most downregulated by apabetalone treatment. This was supported by an observed reduction in the levels of complement proteins, which have been linked to cardiovascular disease and major adverse cardiac events (MACE). A reduction in the overall function of the complement cascade in plasma from cardiovascular disease patients treated with apabetalone was also presented.
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
For further information please visit www.resverlogix.com.
Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on our blog at http://www.resverlogix.com/blog
For further information please contact:
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the Company's Phase 3 clinical trial and the potential role of apabetalone in the treatment of CVD, DM, chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Resverlogix Corp.